Roflumilast

Phase 2/3Completed

1 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Chronic Obstructive Pulmonary Disease (COPD)

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Trial Timeline

Nov 1, 2004 → Mar 1, 2007

NCT ID

NCT00242294

About Roflumilast

Roflumilast is a phase 2/3 stage product being developed by AstraZeneca for Chronic Obstructive Pulmonary Disease (COPD). The current trial status is completed. This product is registered under clinical trial identifier NCT00242294. Target conditions include Chronic Obstructive Pulmonary Disease (COPD).

What happened to similar drugs?

20 of 20 similar drugs in Chronic Obstructive Pulmonary Disease (COPD) were approved

Approved (20) Terminated (3) Active (0)

✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved

✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved

✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved

✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved

✅alefaceptAstellas PharmaApproved

✅AlefaceptAstellas PharmaApproved

✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03381573	Pre-clinical	Completed	Dec 15, 2013	Sep 16, 2022	COPD
NCT02068456	Pre-clinical	Completed	Sep 18, 2012	Apr 26, 2017	Chronic Obstructive Pulmonary Disease
NCT01354782	Phase 1	Completed	May 1, 2011	Sep 1, 2011	Chronic Obstructive Pulmonary Disease
NCT01140542	Phase 2	Completed	Aug 1, 2006	Mar 1, 2008	Diabetes Mellitus Type 2
NCT00246935	Phase 3	Completed	May 1, 2005	Oct 1, 2007	Chronic Obstructive Pulmonary Disease (COPD)
NCT00246922	Phase 3	Completed	Dec 1, 2004	Oct 1, 2007	Bronchial Asthma
NCT00242294	Phase 2/3	Completed	Nov 1, 2004	Mar 1, 2007	Chronic Obstructive Pulmonary Disease (COPD)
NCT00108823	Phase 3	Completed	Oct 1, 2004	—	Chronic Obstructive Pulmonary Disease, COPD
NCT00242307	Phase 2/3	Completed	May 1, 2004	Jun 1, 2007	Bronchial Asthma
NCT00163475	Phase 3	Completed	May 1, 2004	Aug 1, 2005	Asthma
NCT00076076	Phase 3	Completed	Dec 1, 2003	Jun 1, 2005	Asthma
NCT00076089	Phase 3	Completed	Dec 1, 2003	Dec 1, 2005	Chronic Obstructive Pulmonary Disease
NCT00073177	Phase 3	Completed	Nov 1, 2003	—	Asthma
NCT00062582	Phase 3	Completed	Jun 1, 2003	—	Chronic Obstructive Pulmonary Disease
NCT00163527	Phase 3	Completed	Apr 1, 2003	Nov 1, 2005	Asthma
NCT00430729	Phase 3	Completed	Jan 1, 2003	—	Chronic Obstructive Pulmonary Disease

Competing Products

20 competing products in Chronic Obstructive Pulmonary Disease (COPD)

See all competitors

Product	Company	Stage	Hype Score
Levofloxacin 500	Dr. Reddy's Laboratories	Pre-clinical	23
mRNA-0184	Moderna	Phase 1	0
Lubiprostone + Lubiprostone + Placebo	Dr. Reddy's Laboratories	Phase 3	37
macitentan 10 mg	BML, Inc.	Phase 3	32
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
TERN-701	Terns Pharmaceuticals	Phase 1/2	36
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	23
LY3556050 + Placebo	Eli Lilly	Phase 2	35
THB001	Third Harmonic Bio	Phase 1	11
Briquilimab	Jasper Therapeutics	Phase 1/2	26
Briquilimab	Jasper Therapeutics	Phase 1/2	14
Briquilimab	Jasper Therapeutics	Phase 2	29
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	40
LY3461767 + Placebo	Eli Lilly	Phase 1	29
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	44
LY3526318 + Placebo	Eli Lilly	Phase 2	35
Pirtobrutinib	Eli Lilly	Phase 2	42
Ibrutinib + LY3214996	Eli Lilly	Phase 1	21
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	27
LYR-210	Lyra Therapeutics	Phase 2	25